Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Margetuximab by MacroGenics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Margetuximab is under clinical development by MacroGenics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...
Margetuximab by MacroGenics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Margetuximab is under clinical development by MacroGenics and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Margetuximab by MacroGenics for Gastric Cancer: Likelihood of Approval
Margetuximab is under clinical development by MacroGenics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Margetuximab by MacroGenics for Gallbladder Cancer: Likelihood of Approval
Margetuximab is under clinical development by MacroGenics and currently in Phase I for Gallbladder Cancer. According to GlobalData, Phase I...